

Letermovir for preventing cytomegalovirus disease after a stem cell transplant

Information for the public

Published: 31 July 2019

www.nice.org.uk

Letermovir (Prevymis) is available on the NHS as a possible treatment for preventing cytomegalovirus (CMV) reactivation (when the virus becomes active again) and CMV disease in adults if:

- their blood is seropositive (tests positive) for CMV and
- they have had an allogeneic haematopoietic stem cell transplant (a stem cell transplant from a donor).

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

[The NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [CMV Action](#), 0808 802 0030
- [Anthony Nolan](#), 0303 303 0303

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3475-1